Efficacy and Safety of Perampanel as the First Medication for Children with Newly Diagnosed Epilepsy: A Real-World Single-Center Prospective Observational Study - Scorecard - MDSpire
Advertisement
Efficacy and Safety of Perampanel as the First Medication for Children with Newly Diagnosed Epilepsy: A Real-World Single-Center Prospective Observational Study
Clinical Scorecard: Assessment of Perampanel's Effectiveness and Safety as the Initial Treatment in Pediatric Patients with Newly Diagnosed Epilepsy: A Prospective Observational Study at a Single Center
At a Glance
Category
Detail
Condition
Pediatric Epilepsy
Key Mechanisms
Antiseizure medication with a unique mechanism of action
Target Population
Children with newly diagnosed epilepsy
Care Setting
Single-center, prospective observational study
Key Highlights
Seizure-free rate at 12 months was 64.1% among all patients
Seizure-free rate for SeLECTS subgroup was 78.6%
Average adverse events rate was 24.8%, with common AEs including dizziness and drowsiness
Initial mean dosage of Perampanel was 2.3±1.2 mg/day
Retention rate of patients on Perampanel was 93.5%
Guideline-Based Recommendations
Diagnosis
Diagnosis of epilepsy should be confirmed prior to initiating treatment with Perampanel.
Management
Perampanel can be used as initial monotherapy for pediatric patients with epilepsy.
Monitoring & Follow-up
Patients should be monitored for adverse events and seizure frequency during treatment.
Risks
Adverse events may occur, including dizziness, drowsiness, and irritability.
Patient & Prescribing Data
137 pediatric patients with epilepsy, mean age 7.91±2.53 years
Seizure freedom rates improved over time, with higher rates observed at 6 months compared to 12 months.
Clinical Best Practices
Consider slow titration of Perampanel to improve tolerability.
Evaluate seizure freedom at regular follow-up visits.
